Core Insights - TME Pharma N.V. provides updates on its research and development activities, focusing on its cancer and eye disease therapies [2] Group 1: NOX-E36 Developments - TME Pharma has initiated a subsequent study for NOX-E36 while terminating its collaboration with the Singapore Eye Research Institute for glaucoma filtration surgery, which is unrelated to the quality of NOX-E36 [3] - The company plans to launch studies in January 2026 to validate NOX-E36 detection in relevant animal models, facilitating local administration to patients [3][4] - TME Pharma believes that starting this new program will ease the search for new partners to advance NOX-E36 through collaboration, sale, or joint venture [4] Group 2: Market Potential - Fibrosis significantly contributes to treatment failure in glaucoma filtration surgery and is a critical factor in several eye diseases affecting approximately 30 million people in the US, highlighting the market potential for anti-fibrotic therapies like NOX-E36 [5] Group 3: NOX-A12 Developments - TME Pharma is actively discussing potential partnerships for the NOX-A12 program and has kept the glioblastoma clinical trial open for resumption upon finding a suitable partner [6] Group 4: Financial Strategy - As of June 30, 2025, TME Pharma has approximately €2.0 million in cash, reflecting a responsible treasury policy and strict cost control, with no investments made in cryptocurrencies despite a new treasury policy allowing such investments [7] - The company signed a non-binding Letter of Intent with a German Resource Development Company (GRDC) and is conducting due diligence, with shareholder approval contingent on positive outcomes [8] Group 5: Strategic Restructuring - Under the leadership of the new CEO, TME Pharma is undergoing strategic restructuring to unlock the value of its lead assets, NOX-A12 and NOX-E36, while exploring acquisitions and partnerships in stable, profitable businesses to support its drug development [11][18]